Abstracts Archive - Page 2555 of 2607 - ACR Meeting Abstracts

Abstract Number: 714 • 2012 ACR/ARHP Annual Meeting
Line Blot Assay, a Screening Test for Autoantibodies in Systemic Sclerosis (SSc)
Kae Takagi¹, Yasushi Kawaguchi¹, Sayuri Kataoka¹, Yuko Ota², Yuko Okamoto¹, Masanori Hanaoka¹, Hisae Ichida¹, Takahisa Gono¹, Yasuhiro Katsumata¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology,Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Detection of auto-antibody is informative for diagnosis of SSc. Line blot assay (LBA) provides a quantitative in vitro assay for detecting human IgG class…
Abstract Number: 716 • 2012 ACR/ARHP Annual Meeting
Utility of Novel Patient-Reported Outcome Instruments in Predicting Cardiac Involvement and Pulmonary Hypertension in Patients with Systemic Sclerosis
Monique E. Hinchcliff¹, Mary A. Carns², Sofia Podlusky², John Varga³ and Sanjiv J. Shah⁴, ¹Northwestern University, Feinberg School of Medicine, Chicago, IL, ²Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Heart involvement in systemic sclerosis (SSc) includes left ventricular systolic and diastolic dysfunction, right ventricular dysfunction, pericardial disease, and pulmonary hypertension. We recently demonstrated…
Abstract Number: 717 • 2012 ACR/ARHP Annual Meeting
Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative
Lesley Ann Saketkoo¹, Reuben Escorpizo², Kevin J. Keen³, Kim Fligelstone⁴ and Oliver Distler⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, ³Mathematics and Statistics, University of Northern British Columbia, Prince George, BC, Canada, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as…
Abstract Number: 719 • 2012 ACR/ARHP Annual Meeting
Biomarkers of Pulmonary Hypertension in Patients with Scleroderma: A Case-Control Study
Zsuzsanna H. McMahan¹, Florian Schoenhoff², Jennifer van Eyk³, Fredrick M. Wigley⁴ and Laura K. Hummers⁴, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Department of Cardiovascular Surgery, Berne, Switzerland, ³Johns Hopkins University and Cedars Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The objective of this study was to evaluate for an association between various biomarkers and the presence or absence of pulmonary hypertension (PH) in…
Abstract Number: 720 • 2012 ACR/ARHP Annual Meeting
Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Lada Miller¹, Sandra Chartrand¹, Martial Koenig², Jean-Richard Goulet³, Eric Rich¹, Michal Abrahamowicz⁴, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁴Centre Universitaire de Santé McGill (CUSM), Montreal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc). Pulmonary arterial hypertension (PAH) is reportedly the most frequent…
Abstract Number: 721 • 2012 ACR/ARHP Annual Meeting
Measurement of Pulmonary Arteries by Cardiac Magnetic Resonance Imaging: A Simple and Useful Tool for the Detection of Pulmonary Hypertension in Systemic Sclerosis Patients without Overt Cardiac Microvascular Perfusion Defects or Fibrosis
Sandra Chartrand¹, Lada Miller¹, Martial Koenig², Jean-Richard Goulet¹, Eric Rich¹, Anne S. Chin³, Yves Provost³, Carl Chartrand-Lefebvre³, Pauline Gou¹, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Radiology, Hôtel-Dieu de Montréal du CHUM, Montréal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a major complication of systemic sclerosis (SSc). We observed that a significant proportion of our SSc patients with PH as…
Abstract Number: 722 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis Associated Pulmonary Hypertension – Is Pulmonary Veno-Occlusive Disease As Common As They Say?
Benjamin E. Schreiber¹, Greg Keir², D. Dobarro³, Clive Handler⁴, Svetlana Nihtyanova⁵, Jay Suntharaligam⁶, Nicola Sverzelatti⁷, Graham Robinson⁶, David Hansell⁸, Athol U. Wells⁹, Christopher P. Denton¹⁰ and John G. Coghlan¹¹, ¹Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ²Royal Brompton Hospital, United Kingdom, ³Pulmonary Hypertension, Royal Free Hospital, London, United Kingdom, ⁴Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ⁵Department of Rheumatology, Royal Free Hospital, Medical School, London, England, ⁶Royal United Hospital, Bath, United Kingdom, ⁷University of Parma, Parma, Italy, ⁸Royal Brompton Hospital, London, United Kingdom, ⁹Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ¹⁰Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ¹¹National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Recent reviews have suggested a high prevalence of pulmonary veno-occlusive disease (PVOD) amongst patients with systemic sclerosis (SSc) associated pulmonary hypertension (PH). Interlobular septal…
Abstract Number: 723 • 2012 ACR/ARHP Annual Meeting
Renal Dysfunction and Disease Severity in Scleroderma-Associated Pulmonary Arterial Hypertension
Stephen C. Mathai¹, Laura K. Hummers² and Virginia D. Steen³, ¹Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Renal disease is a common complication of scleroderma (SSc). Isolated reduction in glomerular filtration rate (GFR), a marker of impaired renal function, can occur…
Abstract Number: 724 • 2012 ACR/ARHP Annual Meeting
Survival, Hospitalization or Need for Combination Therapy At One Year in Patients with Scleroderma-Associated Pulmonary Arterial Hypertension
Robyn T. Domsic¹, Lorinda Chung², Jessica K. Gordon³, Yona Cloonan⁴, Virginia D. Steen⁵ and PHAROS Investigators⁶, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁶Washington, DC, DC
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Although survival has improved with PAH-specific medications in…
Abstract Number: 725 • 2012 ACR/ARHP Annual Meeting
The Role of Interleukin-23 in Spondyloarthropathy
Jonathan Sherlock¹, Barbara Joyce-Shaikh¹, Scott Turner¹, Cheng-Chi Chao², Manjiri Sathe¹, Jeff Grein¹, Dan Gorman¹, Eddie P. Bowman², Terrill McClanahan¹, Jennifer Yearley¹, Gerard Eberl³, Christopher D. Buckley⁴, Robert Kastelein¹, Robert Pierce¹, Drake LaFace¹ and Daniel Cua⁵, ¹Merck, Palo Alto, CA, ²Drug Discovery, Merck, Palo Alto, CA, ³Institut Pasteur, Paris, France, ⁴Center for Translational Inflammation Research, School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom, ⁵Discovery Research, Merck Research Laboratory, Palo Alto, CA
Background/Purpose: Spondyloarthropathy is characterized by inflammation and bony pathology at the entheseal insertion of tendons to bone. Recent investigations have converged upon interleukin(IL)-23, demonstrating firstly…
Abstract Number: 726 • 2012 ACR/ARHP Annual Meeting
Dynamic in Vivo Imaging of Th17-Mediated Osteoclastic Bone Resorption in Live Bones by Using Intravital Multiphoton Microscopy
Junichi Kikuta and Masaru Ishii, Laboratory of Cellular Dynamics, Immunology Frontier Research Center, Osaka University, Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint synovial inflammation and progressive cartilage/bone destruction. Although various kinds of cell types, such…
Abstract Number: 727 • 2012 ACR/ARHP Annual Meeting
Effects of Odanacatib On BMD and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
Roland Chapurlat¹, Sydney Bonnick², Tobias De Villiers³, Alberto Odio⁴, Santiago Palacios⁵, Boyd Scott⁶, Celine Le Bailly De Tilleghem⁷, Carolyn DaSilva⁶, Albert Leung⁸ and Deborah Gurner⁶, ¹Hôpital Edouard Herriot, Lyon, France, ²Director Osteoporosis Services, Cooper Clinic, Dallas, TX, ³Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, ⁴Alta California Medical Group, Simi Valley, CA, ⁵Instituto Palacios, Madrid, Spain, ⁶Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ⁷MSD Europe Inc., Brussels, Belgium, ⁸Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib (ODN) is a potent, orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN…
Abstract Number: 728 • 2012 ACR/ARHP Annual Meeting
Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis ? – Results of the International Scleroderma Renal Crisis Survey
Marie Hudson¹, Murray Baron², Solene Tatibouet¹, Daniel Furst³, Dinesh Khanna⁴ and International Scleroderma Renal Crisis Study Investigaots⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Montreal
Background/Purpose: Scleroderma renal crisis (SRC) is an infrequent but life-threatening complication of systemic sclerosis (SSc). The outcome of SRC has improved considerably since the advent…
Abstract Number: 729 • 2012 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Underlie Racial Disparities in Lupus Nephritis-Induced End-Stage Renal Disease
Robert P. Kimberly¹, Barry I. Freedman², Carl D. Langfeld³, Devin Absher⁴, Kelly K. Andringa¹, Daniel Birmingham⁵, Elizabeth E. Brown⁶, Mary E. Comeau⁷, Karen H. Costenbader⁸, Lindsey A. Criswell⁹, Jeffrey C. Edberg¹⁰, John B. Harley¹¹, Judith A. James¹², Diane L. Kamen¹³, Joan T. Merrill¹⁴, Timothy B. Niewold¹⁵, Neha Patel¹⁶, Michelle Petri¹⁷, Rosalind Ramsey-Goldman¹⁸, Jane E. Salmon¹⁹, Mark Segal²⁰, Kathy Moser Sivils¹², Betty P. Tsao²¹, Bruce A. Julian¹ and Lupus Nephritis-ESRD Consortium²², ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Biostatistics, Wake Forest University Health Sciences, Winston-Salem, NC, ⁴HudsonAlpha Institute for Biotechnology, Huntsville, AL, ⁵Medicine, Ohio State University Medical Center, Columbus, OH, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Wake Forest University Health Sciences, Winston-Salem, NC, ⁸Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹⁰Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹⁶Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁹Rheumatology, Hospital for Special Surgery, New York, NY, ²⁰Medicine/Nephrology, University of Florida, Gainesville, FL, ²¹Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ²²Medicine, Birmingham, AL
Background/Purpose: The G1 and G2 coding variants in the apolipoprotein L1 gene (APOL1; G1: a compound missense allele (glycine-342/methionine-384) and G2: an in-frame deletion (deletion…
Abstract Number: 730 • 2012 ACR/ARHP Annual Meeting
Disease Modifying Effect of Strontium Ranelate in Experimental Dog Osteoarthritis: Inhibition of Major Catabolic Pathways
Jean-Pierre Pelletier¹, Mohit Kapoor², Daniel Lajeunesse², Hassan Fahmi³ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada, ³Pharmacology, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada
Background/Purpose: To assess the disease modifying (DMOA) effect of strontium ranelate (SrRan) under therapeutic conditions on the progression of structural changes and on the major…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].